FIELD: pharmacology.
SUBSTANCE: invention relates to compounds, compositions thereof, for treatment of infections and neoplasms with structures 
, where R1 is the residue of a compound selected from the group consisting of cytarabine, fludarabine, gemcitabine, clofarabine, cladribine, vidase, dacogen, pentostatin and cladribine or aristermycin, acyclovir, ganciclovir, penciclovir, adefovir, cidofovir, tenofovir, zidovudine and lamivudine; X and Y are independently O, S or NH; and R2 and R3 are independently selected from the group consisting of H, alkyl, phenyl, heteroaryl and the remainder of the vitamin B6 fragment selected from
wherein heteroaryl is an aromatic ring containing from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, and wherein at least one of R2 and R3 is the residue of a fragment of vitamin B6, L is alkyl.
EFFECT: new effective substances for treatment of viral and oncological diseases.
16 cl, 4 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND THEIR APPLICATION | 2012 |
|
RU2648950C2 |
| MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND USE THEREOF | 2012 |
|
RU2707251C2 |
| CONJUGATE SALTS FOR CANCER TREATMENT | 2016 |
|
RU2747528C2 |
| COMBINED THERAPY FOR TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASTIC SYNDROME | 2002 |
|
RU2338535C2 |
| DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | 2016 |
|
RU2748992C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2699985C2 |
| 5'-CAP-TRINUCLEOTIDE COMPOUNDS OR 5'-CAP COMPOUNDS WITH LARGE NUMBER OF NUCLEOTIDES AND THEIR USE FOR RNA STABILIZATION, PROTEIN EXPRESSION AND IN THERAPY | 2019 |
|
RU2811940C2 |
| PHOSPHONATE DERIVATIVES | 2000 |
|
RU2258707C2 |
| METHODS OF TREATMENT | 2020 |
|
RU2822394C1 |
| CONJUGATED ANTISENSE COMPOUNDS AND USE THEREOF | 2014 |
|
RU2697152C2 |
